Allergy
Therapeutics
plc
("Allergy Therapeutics", the "Group" or "Company")
Appointment of Dr. Shaun
Furlong to Board of Directors
11
March 2024 Allergy Therapeutics plc
(AIM: AGY), the integrated commercial biotechnology company
specialising in allergy vaccines, is pleased to announce the
appointment of Shaun Furlong as an Executive Director of the
Company, with effect from 8 March 2024.
Shaun was appointed as the Group's
Chief Financial Officer (CFO) in August 2023, having previously
served as Group Financial Controller since April 2022. He brings
significant financial experience, having held senior finance roles
within blue-chip companies across multiple sectors, including Legal
& General, Hastings Direct, Volution Group and American
Express. Shaun is a Fellow of the Institute of Chartered
Accountants in England and Wales and holds a PhD in polymer
chemistry from the University of Sussex.
Peter Jensen, Chairman of Allergy Therapeutics,
commented: "Shaun has proven himself to
be an invaluable asset to the Company since his appointment as
Group Financial Controller and more recently since his appointment
as Chief Financial Officer last year. Given his professionalism,
strong financial acumen and range of experience, I have no doubt
that he will be an important contributor to the
Board."
Commenting on his appointment, Shaun Furlong
said: " I am delighted to take on
an expanded leadership role as an Executive Director and look
forward to working alongside the other members of the
Board."
Additional Information in respect of the AIM
Rules:
Shaun Antony Furlong, aged 48, holds
an interest in 1,500 ordinary shares in the Company. In the
previous five years, Shaun was a director of SAF Management
Services Limited. The Company confirms that there is no other
information in relation to Shaun's appointment that is required to
be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of
the AIM Rules for Companies.
For further information,
please contact:
Allergy Therapeutics
Manuel Llobet, Chief Executive
Officer
Shaun Furlong, Chief Financial
Officer
+44 (0)1903 845 820
Panmure Gordon (Nominated Adviser and
Broker)
Emma Earl, Freddy Crossley, Mark
Rogers, Corporate Finance
Rupert Dearden, Corporate
Broking
+44 (0)20 7886 2500
ICR
Consilium
Mary-Jane Elliott / David Daley /
Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an
international commercial biotechnology company, headquartered in
the UK, focussed on the treatment and diagnosis of allergic
disorders, including aluminium free immunotherapy vaccines that
have the potential to cure disease. The Group sells proprietary and
third-party products from its subsidiaries in nine major European
countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development
includes vaccines for grass, tree, house dust mite and peanut. For
more information, please see www.allergytherapeutics.com.